HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP

被引：0
|
作者：
Muggiano, A. [1 ]
Mulas, C. [1 ]
Fiori, B. [1 ]
Liciardi, G. [1 ]
Pintus, M. [1 ]
Tanca, L. [1 ]
Tedde, A. [1 ]
Turno, R. [1 ]
Desogus, A. [1 ]
机构：
[1] Osped Oncolog A Businco, Div Med Oncol 1, Cagliari, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [41] Long-term follow-up after high-dose therapy for high-risk multiple myeloma
    B Barlogie
    S Jagannath
    S Naucke
    S Mattox
    D Bracy
    J Crowley
    G Tricot
    R Alexanian
    Bone Marrow Transplantation, 1998, 21 : 1101 - 1107
  • [42] Adjuvant Imatinib Treatment after R0 Resection for Patients With High-Risk Gastrointestinal Stromal Tumors: A Median Follow-Up of 44 Months
    Jiang, Wei-Zhong
    Guan, Guo-Xian
    Lu, Hui-Shan
    Yang, Ying-Hong
    Kang, De-Yong
    Huang, He-Guang
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (07) : 760 - 764
  • [43] A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients.
    Si, L.
    Mao, L. L.
    Chi, Z. H.
    Cui, C. L.
    Sheng, X. N.
    Li, S. M.
    Tang, B. X.
    Guo, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
    Kilbridge, KL
    Cole, BF
    Kirkwood, JM
    Haluska, FG
    Atkins, MA
    Ruckdeschel, JC
    Sock, DE
    Nease, RF
    Weeks, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1311 - 1318
  • [45] A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
    Si, Lu
    Wang, Xuan
    Kong, Yan
    Lian, Bin
    Chi, Zhi Hong
    Cui, Chuan Liang
    Sheng, Xi Nan
    Mao, Li Li
    Tang, Bi Xia
    Li, Si Ming
    Yan, Qiao Xie
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
    Goodman, Rachel S.
    Lawless, Aleigha
    Woodford, Rachel
    Fa'ak, Faisal
    Tipirneni, Asha
    Patrinely, J. Randall
    Yeoh, Hui Ling
    Rapisuwon, Suthee
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Long, Georgina V.
    Sullivan, Ryan J.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Johnson, Douglas B.
    JAMA NETWORK OPEN, 2023, 6 (08) : E2327145
  • [47] Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial
    Grob, J. J.
    Jouary, T.
    Dreno, B.
    Gutzmer, R.
    Hauschild, A.
    Leccia, M. T.
    Landthaler, M.
    Asselineau, J.
    Garbe, C.
    Pehamberger, H. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [48] Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b
    Moschos, SJ
    Kirkwood, JM
    Konstantinopoulos, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 11 - 14
  • [49] High dose interferon alpha 2b as adjuvant therapy in high-risk resected malignant melanoma: 10 year experience of patients treated in Northern Ireland
    Jain, S. K.
    Mulholland, L.
    McCourt, C.
    Connolly, D.
    Khan, E. E.
    Wilson, J.
    Brady, D.
    McAleer, J. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 401 - 401
  • [50] Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis
    Hauschild, A
    Weichenthal, M
    Balda, BR
    Becker, JC
    Wolff, HH
    Tilgen, W
    Schulte, KW
    Ring, J
    Schadendorf, D
    Lischner, S
    Burg, G
    Dummer, R
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2883 - 2888
12345